Lanadelumab Active in Angioedema With C1 Inhibitor Deficiency

Share this content:
Lanadelumab Active in Angioedema With C1 Inhibitor Deficiency
Lanadelumab Active in Angioedema With C1 Inhibitor Deficiency

THURSDAY, Feb. 23, 2017 (HealthDay News) -- For patients with hereditary angioedema with C1 inhibitor deficiency, the new kallikrein inhibitor lanadelumab is associated with reduced cleavage of high-molecular-weight kininogen and fewer angioedema attacks, according to a study published in the Feb. 23 issue of the New England Journal of Medicine.

Aleena Banerji, M.D., from Massachusetts General Hospital in Boston, and colleagues conducted a phase 1b trial involving patients with hereditary angioedema with C1 inhibitor deficiency. Participants were randomized to receive lanadelumab (24 patients) or placebo (13 patients) in two administrations 14 days apart with a total dose of 30, 100, 300, or 400 mg.

The researchers observed no discontinuations due to adverse events, serious adverse events, or deaths among patients receiving lanadelumab. There were dose-proportional increases in lanadelumab serum concentrations, with a mean elimination half-life of about two weeks. At a dose of 300 or 400 mg, lanadelumab reduced cleavage of high-molecular-weight kininogen in plasma to levels approaching that of patients without hereditary angioedema with C1 inhibitor deficiency. The 300-mg and 400-mg groups had 100 and 88 percent fewer attacks, respectively, from day eight to day 50 than the placebo group. Twenty-seven percent of patients in the placebo group, and 100 and 82 percent of those in the 300-mg and 400-mg groups, respectively, were attack-free.

"In this small trial, administration of lanadelumab to patients with hereditary angioedema with C1 inhibitor deficiency reduced cleavage of high-molecular-weight kininogen and attacks of angioedema," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Dyax, which manufacturers lanadelumab and funded the study.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Gender Nonconformity Linked to Students' Mental Distress

Gender Nonconformity Linked to Students' Mental Distress

For male students, gender nonconformity strongly associated with substance use

Participation Up With Online Diabetes Prevention Program

Participation Up With Online Diabetes Prevention Program

But weight loss no different for online, in-person DPP for obese/overweight veterans with prediabetes

Net Benefit of Anticoagulants for A-Fib Varies With Stroke Rate

Net Benefit of Anticoagulants for A-Fib Varies With ...

Benefit of warfarin anticoagulation varies with varying published stroke rates

is free, fast, and customized just for you!




Already a member?

Sign In Now »